The brk gene encodes a non-receptor protein tyrosine kinase that consists of single SH3, SH2 and catalytic domains. Although BRK shows strongest sequence similarity to members of the SRC family of PTKs, there are several key structural and regulatory dierences that place it on its own amongst non-receptor PTKs. In this study we have isolated genomic DNA clones corresponding to the human brk locus and used these to determine the intron-exon structure of the brk gene. The genomic structure of brk consists of 8 exons, whose boundaries are distinct from other non-receptor PTK family members, again indicating a structural and functional divergence. Alternate splicing of the primary brk transcript generates a distinct mRNA which encodes a truncated protein consisting of an SH3 domain and a novel C-terminal proline rich sequence. Using an antiserum raised to the SH3 domain, we have demonstrated that the product of this alternate brk transcript is expressed in the human breast tumour cell line T-47D. We have previously reported that expression of a tumour derived brk cDNA in mouse embryonic ®broblasts and human mammary epithelial cells supports anchorage independent growth, and in the latter potentiates the mitogenic response to epidermal growth factor. The protein encoded by the genomic sequence derived from normal human tissue is identical to that encoded by the tumour derived cDNA, and therefore the altered growth regulation is not associated with mutations within brk. In addition, we have identi®ed a 5' genomic region that has promoter activity. The brk gene has been assigned to chromosome 19q 13.3-13.4 usinḡ uorescence in situ hybridisation (FISH).
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The non-receptor class of PTKs represents a collection of cellular enzymes involved in intracellular signalling which have a variety of structures, subcellular localisations, substrates and modes of regulation (reviewed Bolen, 1993) . Recent studies have demonstrated that the total PTK activity in extracts of malignant tissue was signi®cantly higher when compared with extracts from benign or normal breast tissue (Hennipman et al., 1989; Ottenho-Kal et al., 1992; Lower et al., 1993; Bolla et al., 1993) . Moreover, the increase in the cytosolic fractions was found to be a prognostic indicator of decreased 3 year disease free survival (Hennipman et al., 1989; Bolla et al., 1993) .
While identifying PTKs expressed in human metastatic breast tumours, in order to assess their role in mammary tumorigenesis, we have recently described the cDNA cloning of brk from a metastatic human breast cancer and human breast carcinoma cell lines (Mitchell et al., 1994) . The predicted BRK protein contains SH3, SH2 and PTK catalytic domains; this arrangement and sequence similarity allies BRK most closely with the SRC-family of PTKs. However, BRK diers from SRC-like kinases in several respects, most notably in its lack of an Nterminal extension and consensus sequences for fatty acylation and membrane association. Similar to SRC, BRK has a tyrosine close to its C-terminus (Tyr-447). Negative regulation of SRC kinase activity is mediated through phosphorylation of this C-terminal tyrosine (Tyr 527), and results from an interaction of phosphorylated Tyr 527 with the amino terminal SH2 domain (Xu et al., 1997; Sicheri et al., 1997) . In the case of SRC and related proteins, this regulatory tyrosine can be phosphorylated by the non-receptor PTK CSK Okada et al., 1991; Bergman et al., 1992) . Unlike SRC kinases in which mutation of Tyr 527 (and its equivalent) to Phe results in deregulated kinase activity and increased transforming ability (Kmiecik and Shalloway, 1987; Piwnica-Worms et al., 1987; Cartwright et al., 1987; Amrein and Sefton, 1988; Abraham and Veilette, 1990; Ziegler et al., 1989; Davidson et al., 1994a) , mutation of Tyr-447 to Phe signi®cantly decreases BRK's capacity to induce anchorage-independent growth (Kamalati et al., 1996) .
Initial expression studies have detected low levels of brk transcripts in some human breast tumours and breast tumour cell lines, but not in normal breast tissue. These studies have now been extended and, using a speci®c monoclonal antibody, we have found BRK to be expressed in a signi®cant proportion of breast tumours (Barker et al., 1997) . In addition, expression of BRK in mammary epithelial cells potentiates both their anchorage independent proliferation and their mitogenic response to epidermal growth factor (Kamalati et al., 1996) , implying a role for BRK in growth regulation and potentially, tumour development. Here we present the isolation and characterisation of genomic clones corresponding to the human brk locus.
Isolation and sequencing of brk genomic clones
A human placental genomic library was screened with a radiolabelled probe corresponding to the human brk coding region. From a screen of 1610 6 clones, six independent positive clones were identi®ed (l1-6, Figure 1a ). Restriction mapping and Southern analysis, using the brk cDNA as a probe, indicated that the six overlapping clones spanned approximately 33 kilobase pairs (kb) and contained all of the corresponding cDNA sequence. Restriction fragments that hybridised to the brk cDNA were subcloned and sequenced usinḡ anking vector primers and oligonucleotides corresponding to the brk cDNA sequence. These studies demonstrated that the genomic clones isolated did indeed represent the brk locus, and the protein encoded by the normal genomic sequence was identical to that encoded by the tumour cell line derived cDNA described in previous studies. In addition, the sequencing studies identi®ed that the brk gene consists of 8 exons. Primers that¯anked the introns were used to amplify brk intronic sequence from the genomic clones. Together with restriction mapping and Southern analysis it was determined that the brk locus spans 10 kb (Figure 1b ).
Genomic organisation of the human brk gene
Intron-exon boundaries were sequenced and determined by comparing genomic and cDNA sequences, all of which ®tted the GT. . . AT consensus for the 5' and 3' ends of introns (Mount, 1982) (Table 1) . As BRK shows the highest degree of sequence similarity to the SRC family of non-receptor PTKs the genomic structure of brk was ®rst compared to that of the src family and then, in addition, to the known genomic structures of two other non-receptor PTK families, csk/matk (Brauninger et al., 1993; Avraham et al., 1995) and btk/txk (Hagemann et al., 1994; Ohta et al., 1994 Ohta et al., , 1996 , which have similar protein structures. brk has 2 exon boundaries that are conserved with src family members. The ®rst is between exons 1-2 of brk and exons 5-6 of src, which lies at the boundary separating the SH3 and SH2 encoding exons. This splice site is the only one that is conserved between brk and members of the csk/matk and btk/txk families. The second is between exons 7-8 of brk and exons 11-12 of src, and separates exons encoding the C-terminal region of the kinase domain ( Figure  2 ). Brk, however, does have a high degree of structural similarity to Dsrc41, a recently identi®ed Drosophila src related gene (Takahashi et al., 1996) . Six out of seven of brk's exon boundaries are conserved with the Dsrc41 gene, which has 9 exons ( Figure 2 ). Figure 1 Schematic representation of the human brk gene showing selected restriction enzyme sites, the relative positions of the lambda phage clones (a) and the intron/exon structure (b). Coding and non-coding exons are represented by black and white boxes respectively. The 1.9 kb SacI fragment containing exon 1 is shown enlarged (c) to show the position of the 0.8 kb NcoI fragment (P), the 3' of which encompasses the translation initiation site, used in the transcription reporter assays. A human placental genomic library in the Lambda FixII vector (Stragagene) was screened using Hybond N membranes (Amersham).
32 p radiolabelled DNA probes were hybridised to membranes according to manufacturer's instructions. Filters were washed in 26SSC, 0.1% SDS at 658C and ®nally in 0.16SSC, 0.1% SDS at 658C. All clones were characterised by restriction mapping using the brk cDNA fragments as probes in Southern blot analysis. Restriction fragments that hybridised to the brk cDNA were subcloned into pBluescript (Stratagene) and sequenced by the dideoxy method (Sanger et al., 1977) using Sequenase Version 2 (USB), or automatically using a Taq Dye Terminator kit (Applied Biosystems) and an ABI 373A sequencing machine. Intron sizes were either directly calculated from the restriction map or determined using exon speci®c oligonucletides in the polymerase chain reaction using genomic lambda clones as the template DNA. Use was also made of the sequencing primer sites in the Bluescript vector to locate exons within subclones. The positions of the exon speci®c oligonucleotides within the brk cDNA (X78549) are as follows: sense primers 1 ± 17, 259 ± 279, 485 ± 502, 658 ± 676, 700 ± 721, 862 ± 883; antisense primers 360 ± 380, 478 ± 498, 674 ± 695, 842 ± 862, 989 ± 1008, 1356 ± 1376. Ampli®cations were carried out in 50 ml volumes containing 1 ± 10 ng of template, 60 mM KCl, 15 mM Tris-HCl (pH8.8), 2.25 mM MgCl 2 , 200 mM of each dNTP, 20 pmol of each primer and 2U of Taq polymerase. The PCR temperature cycle parameters were; 948C for 1 min, 558C for 1 min, 728C for 2 mins for 30 cycles. PCR products were analysed by agarose electrophoresis and then veri®ed, where possible, by digestion with restriction enzymes known to have sites within the ampli®ed introns Analysis of the putative brk promoter region Previous cDNA cloning, 5' RACE PCR and Northern blotting studies indicated that full length brk cDNA clones had been isolated (Mitchell et al., 1994) . In order to determine whether the genomic clones isolated contained sequences with promoter activity an NcoI fragment (P, Figure 1c ) which contained 0.8 kb of sequence upstream of the brk translation initiation site was subcloned into the promoter-less luciferase reporter vector pGL3 basic (brkpGL3). The breast tumour cell line T-47D, which expresses BRK, was transfected with either empty reporter vector, brkpGL3 or SV40 pGL3 which contains the SV40 early promoter/enhancer. A high level of promoter activity was observed in cells transfected with brkpGL3 when compared to the empty vector, the presence of fragment P conferring 300-fold enhanced gene expression (Figure 3) . The sequence of fragment P and potential regulatory elements are shown in Figure 4 .
Identi®cation of an alternate form of BRK protein
During the isolation of brk cDNAs we identi®ed a cDNA clone, lm5, which had a 122 base pair deletion 3' of the SH3 coding region. Following the characterisation of the brk gene, it was found that the deleted region corresponded to exon 2, and that lm5 probably represented an alternatively spliced brk transcript ( Figure 5a ). As a result of this deletion, the open reading frame is shifted and terminates 172 base pairs further 3'. The predicted protein encoded by lm5 is 134 amino acids long (15 kDa), comprising the N-terminal SH3 domain of BRK and a novel proline rich sequence (Figure 5b) . In order to examine whether the Figure 2 Exon boundaries relative to the BRK, SRC, CSK and DSRC41 amino acid sequences. The amino acid were aligned using Clustal W(1.6). Amino acids at exon/intron boundaries are underlined and in bold letters. If two amino acids are underlined and in bold the exon/intron boundaries are between two codons whereas, if only 1 amino acid is marked, the exon/intron boundary is within the codon Figure 3 Promoter activity of fragment P. T-47D cells were transfected with either empty luciferase reporter construct (pGL3) (Promega), the reporter construct containing the upstream brk fragment P (pGL3 brk), or pGL3 containing the SV40 promoter and enhancer sequences (pGL3 SV40) (Promega). For transient transfections, 2610 5 cells were plated per well of a six well dish and transfected using 5 ml of LIPOFECTAMINE reagent (Life Technologies), 1 mg of reporter DNA construct, and 0.5 mg of pCMVb-Gal as a transfection control. Cells were harvested 40 ± 48 h post transfection. Luciferase and b-galactosidase assays were carried out using commercially available reagents (Promega). The ®gure represents the average of four independent experiments. The error bars indicate the standard deviations Figure 4 Nucleotide sequence of the promoter fragment P. Arrows indicate the 5' positions of the brk cDNAs and the 5' RACE PCR generated product (Mitchell et al., 1994) . The translation initiation site is underlined and putative regulatory elements are boxed and named alternative BRK protein was expressed, we raised a polyclonal rabbit antiserum against a glutathione-Stransferase lm5 fusion protein. The anity puri®ed antiserum was used to probe Western blots of breast tumour cell line lysates (T-47D, CAL51) and Hb4a cells transfected with expression vectors encoding full length BRK, the putative product of lm5, or empty vector (Figure 6 ). A protein with the same mobility as that in Hb4a cells transfected with lmt5 was detected in T-47D cells, which also express the full length BRK protein ( Figure 6) (Barker et al., 1997) . No BRK proteins were detected in lysates from CAL51 cells, which have been shown to be negative for brk mRNA (Barker et al., 1997) .
Chromosome localisation of the human brk locus
Fluorescence in situ hybridisation was carried out using the brk genomic phage clone l2. Twenty metaphase spreads were analysed, 90% of which had signals which localised to 19q13.3-13.4 (Figure 7 ).
Discussion
In this study we have characterised genomic clones corresponding to the human brk gene. The predicted protein sequence encoded by the normal brk genomic clones was identical to that encoded by the breast tumour cell line cDNA used in previous studies, therefore expression of normal brk is sucient for deregulation of mammary epithelial cell proliferation (Kamalati et al., 1996) . The brk gene consists of 8 exons which span approximately 10 kb, compared with genomic loci of the coding region of csk (Brauninger et al., 1993) and of src (Tanaka et al., 1987; Anderson et al., 1985; Parker et al., 1985) spanning genomic distances of 4.9 kb (exons 2-12) and 15 kb (exons 2-12), respectively. Although BRK shows the highest degree of amino acid similarity to the SRC family of non-receptor PTKs, the brk gene has only 2 exon boundaries that are conserved with this family. However, a striking structural similarity is seen between brk and Dsrc41, a recently identi®ed Drosophila src-related gene which is the closest relative of vertebrate src found so far in this organism (Takahashi et al., 1996) . Six out of seven of brk's exon boundaries are conserved with the Dsrc41 gene, For the production of glutathione-Stransferase BRK SH3 domain fusion protein, the cDNA lm5 was inserted into the EcoRI-XhoI sites of pGEX 5X-2 (Pharmacia), expressed in bacteria and anity puri®ed using glutathione sepharose (Pharmacia) according to the supplier's instructions. Rabbits were immunised with the puri®ed fusion protein and a polyclonal antiserum was anity puri®ed using cleaved BRK SH3 protein crosslinked to Actigel ALD (Sterogene Bioseparations Inc.) according to the supplier's instructions. Lysates, made in SDS ± PAGE sample buer from cultured cells, were resolved by SDS ± PAGE and electrophoretically transferred to`Hybond-ECL' membranes (Amersham). Blots were blocked in PBS/10% w/v non-fat dried milk. Antibody incubations were in PBS/10% FCS, and washes were in PBS/0.1% v/v Tween-20. Immunoglobulins were detected using horseradish peroxidase conjugated donkey antibodies to rabbit immunoglobulins (Amersham) and`ECL' detection reagents (Amersham). The mammary cell line Hb4a, derived as described (Stamps et al., 1994) , was cultured in RPMI 1640, 10% foetal bovine serum (FBS), hydrocortisone (5 mg/ml), cholera toxin (0.1 mg/ml) and insulin (5 mg/ml). T-47D (ATCC-HTB-133) and Cal51 (Gioanni et al., 1990) were routinely cultured in DMEM/10% FBS which has 9 exons. Interestingly, BRK has a higher amino acid sequence identity (45%) with DSRC41 than with human SRC (44%). Dsrc41 only shares two conserved exon boundaries with vertebrate src, these being those conserved between brk and src. Taken together with the key structural and regulatory dierences between BRK and SRC, these studies indicate that brk is on its own amongst non-receptor PTKs described to date. However, brk is likely to share a common ancestor with Dsrc41. By characterisation of additional brk cDNAs, we have demonstrated that alternative processing of the primary brk transcript results in the splicing out of exon 2 and the juxtaposition of exons 1 and 3. As a result of this splicing, the open reading frame is shifted and terminates 172 bp 3'. This alternate brk mRNA encodes a truncated protein consisting of an SH3 domain and a novel Cterminal proline rich sequence, which we have demonstrated to be expressed in a human breast carcinoma cell line that expresses the full length BRK protein.
Members of the src family of PTKs use alternative splicing to generate speci®c protein isoforms. Through the use of alternate exon 7s, which encode the end of the SH2 domain and the start of the catalytic domain, the fyn gene encodes two dierent tyrosine kinase isoforms. While one protein (p59 fynB ) is abundantly expressed in the brain, the alternative product (p59 fynT ) is found in cells of haematopoietic lineages, especially T lymphocytes, and has distinct catalytic properties (Cooke et al., 1989; Davidson et al., 1994b) . Similarly, neuronal speci®c isoforms of c-SRC are generated by the use of additional exons NI and NII which lie between the SH3 domain encoding exons 3 and 4. Inclusion of these exons in brain mRNA yields transcripts capable of encoding c-SRC products possessing 17 additional amino acids (Levy et al., 1987; Martinez et al., 1987; Pyper and Bolen, 1990) .
It is worthy of note that the boundary between exons 1 and 2 in brk, which separates SH3 and SH2 coding exons, is conserved within members of the src, csk and btk families. It would therefore be interesting to determine whether the latter genes use the same mechanism to generate similar alternative protein isoforms. The truncated form of BRK may regulate the action of full length BRK by competing for interacting SH3 binding proteins or, alternatively, may have a distinct function of its own dependent on its novel C-terminal proline rich region.
An 0.8 kb 5' genomic fragment (P) that was predicted to encompass the transcriptional start sites of the brk mRNA has been characterised. Using a promoter-less luciferase reporter construct, this fragment demonstrated a high level of promoter activity in the T-47D cell line. These studies would therefore indicate that regulatory sequences that control the transcription of the brk gene are present in fragment P. Fragment P did not contain a classical TATA box, however a number of nucleotide sequences that Figure 7 Localisation of the human brk gene by¯uorescence in situ hybridisation to 19q13.3-13.4. Fluorescence in situ hybridisation (FISH) was performed as previously described (Shipley et al., 1993) . Brie¯y, the brk genomic clone l2 was labelled with biotin, 80 ng of which was mixed with 2 mg of CotI DNA (BRL) and resuspended in 10 ml of hybridisation mix prior to hybridising to normal human chromosomes. After washing slides stringently the probe was detected with avidin FITC and the chromosomes counterstained with PI (propidium iodide) and banded with DAPI (4,6-diamidino-2-phenylindole). Images were captured using a Zeiss Axioplan microscope with the appropriate ®lter and a cooled CCD camers (Photometrics, Arizona) attached to an Apple Macintosh computer with SmartCapture software (Digital Scienti®c, Cambridge UK). The chromosome banding pattern was enhanced using the software to allow accurate localisation of the probe Table 1 Exon-intron boundaries of the human brk gene Exon and intron sequences are shown in uppercase and lowercase letters, respectively 5' Splice Donor 3' Splice Donor
ACGTCCTGTCGGgtgcggcccc ----tctccctcccagTGCGGGACAC P C R K H E P Exon 3 ± 4
CCCTGCCGGAAGgtagccgctc ----ctcttcctccagCACGAGCCTG
AGCTGCTCCGCGgtgagtggca ----tcccctctgcagACTCTGATGA R L I K E D V Exon 6 ± 7
AGGCTTATCAAGgtagggccct ----ggctgattGcagGAGGACGTCT V P Y P G M S N Exon 7 ± 8
TGCCCTACCCAGgtactgtccc ----tgtcggccgcagGCATGTCCAA correspond to known cis-acting elements were identi®ed, including Sp1 (Briggs et al., 1986) , the STAT1 and 3 binding sis inducible element (SIE) (Horvath et al., 1995) , AP2 (Imagawa et al., 1987) and NFkB (Kunsch et al., 1992) . However it remains to be determined whether these motifs play a functional role in the regulation of brk transcription. Using FISH, we have mapped brk to the telomeric region of the long arm of chromosome 19. Whole arm gains or ampli®cation of this region of chromosome 19 are not frequently observed in breast tumours and breast tumour cell lines (Ried et al., 1995; Thompson et al., 1993; Guan et al., 1994; Muleris et al., 1994; Kallioniemi et al., 1994) . Moreover, breast tumour cell lines that express high levels of BRK protein do not have increases in copy number of the brk gene (PJM, KTB unpublished results). Future studies would be required to determine whether the increases in BRK expression observed in breast tumours and tumour cell lines are due to changes in the regulation of brk transcription.
